1d
Zacks.com on MSNNVO Q4 Earnings Beat Estimates, GLP-1 Drugs Boost Sales, Stock UpNovo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the ...
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...
Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...
Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...
Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results